• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oric Pharmaceuticals, Inc. - Common Stock (NQ:ORIC)

13.50 +0.57 (+4.41%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Oric Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
These Analysts Revise Their Forecasts On ORIC Pharmaceuticals After Q4 Results ↗
March 12, 2024
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) reported a loss for the fourth quarter on Monday. 
Via Benzinga
News headline image
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
March 11, 2024
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
March 06, 2024
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
March 05, 2024
From ORIC Pharmaceuticals
Via GlobeNewswire
ORIC Pharmaceuticals Inc. (NASDAQ: ORIC) is a Stock Spotlight on 3/1
March 01, 2024
Via Investor Brand Network
News headline image
Where ORIC Pharmaceuticals Stands With Analysts ↗
December 13, 2023
 
Via Benzinga
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 01, 2024
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
February 29, 2024
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results. 
Via Benzinga
News headline image
Analyst Expectations for ORIC Pharmaceuticals's Future ↗
October 23, 2023
 
Via Benzinga
News headline image
Hormel Foods Reports Upbeat Earnings, Joins Pure Storage, Okta, Papa John's International And Other Big Stocks Moving Higher On Thursday ↗
February 29, 2024
U.S. stocks were higher, with the Nasdaq Composite gaining around 50 points on Thursday. 
Via Benzinga
Topics Stocks
News headline image
ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
February 14, 2024
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
MicroMarvel - ORIC Pharmaceutical - Fights Cancer ↗
February 07, 2024
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers in the United States. 
Via Talk Markets
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
January 31, 2024
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Announces $125 Million Private Placement Financing
January 22, 2024
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
Final Boarding Call: 3 Stocks Set for a Sky-High Surge ↗
January 09, 2024
Although the bears hate these high potential stocks, other bullish factors suggest the pessimists are due for an unpleasant surprise. 
Via InvestorPlace
News headline image
ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones
January 08, 2024
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development
December 11, 2023
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
3 Stocks at the Forefront of Personalized Medicine Trend ↗
December 05, 2023
Unveiling the impact of personalized medicine stocks, transforming patient care, and propelling market growth seamlessly 
Via InvestorPlace
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
December 01, 2023
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
November 09, 2023
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
November 06, 2023
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 03, 2023
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting
November 02, 2023
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
Meta To Rally Over 42%? Here Are 10 Top Analyst Forecasts For Thursday ↗
October 26, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile
October 21, 2023
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023
October 17, 2023
Company to host a conference call and webcast on Saturday, October 21, 2023, at 9:00 am ET featuring Dr. Alexander Spira to discuss initial data and potential of ORIC-114 in EGFR/HER2 mutated cancers 
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 06, 2023
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2023 ↗
September 22, 2023
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap